ClinicalTrials.gg
RecruitingNCT07481734TESA-LIVERUpdated Nov 12, 2026

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease

A Phase 2 interventional study of Tesamorelin and Placebo in Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis and Hepatic Steatosis, sponsored by Hudson Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hudson Biotech · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
35th of 89
120 · median 112
Started
2026
with 7 others
Phase 2
20 of 142
3 open now
Primary completion
2027-02
later than 33 of 53 live
Registered
137th of 142
by date

Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 35th largest by planned enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2026, is one of 20 in phase 2, reaches primary completion later than 33 of the 53 other live ones, and was the 137th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.

Read the detailed description

Fatty liver disease (MASLD/NAFLD) is common and may progress to steatohepatitis and fibrosis. There are limited pharmacologic options that directly and durably reduce hepatic steatosis while also improving metabolic risk. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that increases endogenous pulsatile growth hormone secretion and can influence lipid metabolism. Prior randomized studies of tesamorelin have shown reductions in hepatic fat fraction in populations with NAFLD, using magnetic-resonance-based quantification and paired histology in subsets. The primary efficacy endpoint is change in liver fat (MRI-PDFF) from baseline to week 52. Secondary endpoints include MRI-PDFF responder rate (>=30% relative decline), changes in liver enzymes and noninvasive fibrosis measures, metabolic outcomes (glucose, HbA1c, HOMA-IR, lipids), and safety/tolerability outcomes. In this protocol, eligible adults with elevated liver fat on MRI-PDFF are randomized 1:1 to tesamorelin or placebo. Study medication is self-administered once daily by subcutaneous injection.

Dose reduction rules are included for elevated IGF-1 while preserving the blind.

Participants complete study visits at baseline and at weeks 4, 12, 24, 36, and 52 (end of treatment), plus a safety follow-up at week 56. MRI-PDFF is performed at baseline, week 24, and week 52. Transient elastography (FibroScan) and standard laboratory panels are collected at prespecified visits. A voluntary liver-biopsy sub-study is offered to evaluate histologic activity and fibrosis.

03

Conditions studied

  • Metabolic Associated Steatotic Liver Disease
  • Nonalcoholic Steatohepatitis
  • Hepatic Steatosis

Keywords

  • Tesamorelin
  • GHRH analog
  • growth hormone axis
  • hepatic fat fraction
  • MRI-PDFF
  • transient elastography
  • teatohepatitis
  • fibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age 18 to 75 years, able to provide .
  • Evidence of hepatic steatosis consistent with MASLD/NAFLD, defined as MRI-PDFF >=10% at screening (or equivalent imaging documentation if MRI-PDFF was performed within the prior 8 weeks).
  • Fibrosis risk compatible with non-cirrhotic disease (e.g., FibroScan liver stiffness below a prespecified threshold and no clinical evidence of portal hypertension).
  • Stable body weight (+/-5%) for at least 3 months prior to screening.
  • If on diabetes, lipid-lowering, antihypertensive, or weight-loss medications, regimen is stable for at least 3 months prior to screening and expected to remain stable through week 52.
  • Willingness and ability to self-administer daily subcutaneous injections (or have a trained caregiver).
  • For participants of : agreement to use reliable during treatment and for 30 days after the last dose; negative pregnancy test at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Significant alcohol consumption consistent with alcohol-associated liver disease (e.g., >20 g/day for women or >30 g/day for men for sustained periods).
  • Other chronic liver diseases (e.g., chronic , chronic with viremia, hepatitis, Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency).
  • Known cirrhosis or decompensated liver disease; or -proven stage 4 fibrosis if baseline biopsy is performed.
  • Poorly controlled diabetes or conditions increasing ocular risk (e.g., at or above a protocol threshold; active/untreated diabetic retinopathy).
  • Use of exogenous growth hormone or GHRH analogs within the past 12 months.
  • Chronic systemic or chronic use of medications known to induce or worsen steatosis or liver injury (e.g., amiodarone, tamoxifen, methotrexate).
  • Active or high risk for recurrence judged unsafe by investigators.
  • to MRI (e.g., certain implanted devices) if MRI-PDFF is required.
  • Pregnancy or breastfeeding.
  • Known to tesamorelin or formulation (e.g., mannitol).
  • Bariatric surgery within the last 12 months, or planned bariatric surgery during the study period.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Experimental: Tesamorelin 2 mg subcutaneous once daily (with dose-reduction algorithm for elevated I

    Drug: Tesamorelin · Drug: Placebo · Behavioral: Standardized lifestyle counseling

  • Experimental
    Placebo Comparator: Matching placebo subcutaneous once daily

    Drug: Tesamorelin · Drug: Placebo · Behavioral: Standardized lifestyle counseling

Interventions

  • for injection, 2 mg SC once daily; participant self-administration after training. Dose may be reduced to 1 mg daily if IGF-1 z-score meets protocol threshold.

  • DrugPlacebo

    for injection (mannitol-based, identical appearance), SC once daily.

  • BehavioralStandardized lifestyle counseling

    dietary guidance and physical activity recommendations,delivered at baseline and reinforced at each visit.

06

What researchers measure

Primary outcomes

  1. Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points)

    MRI-PDFF performed at baseline and week 52; central blinded read.

    Time frame: 52 weeks

Secondary outcomes

  1. MRI-PDFF responder rate (>=30% relative decline from baseline)

    Responder analysis using MRI-PDFF values (baseline vs week 52).

    Time frame: 52 weeks

  2. Change in ALT

    Clinical chemistry panel at baseline and scheduled visits.

    Time frame: 52 weeks

  3. Change in liver stiffness by transient elastography

    FibroScan liver stiffness measurement; performed per site SOP.

    Time frame: 52 weeks

  4. Change in controlled attenuation parameter (CAP) by transient elastography

    FibroScan CAP measurement

    Time frame: 52 weeks

  5. Change in fasting glucose

    Time frame: 52 weeks

  6. Change in fasting lipids

    Time frame: 52 weeks

  7. Change in visceral adipose tissue (VAT) volume

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 19, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Feb 14, 2027
CompletionEst.
Feb 17, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Title Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07481734
Lead sponsor
Hudson Biotech
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Feb 2, 2026
Primary completion
Feb 14, 2027 (estimated)
Completion
Feb 17, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Seni S Lu, Phd
Contact
Seni-Lu@beijing-biotech.com
+86 13076790030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tesamorelin

Start the discussion